Page 1 of 13
Site Disclaimer
Site Disclaimer This Site is Not a Source of Medical Advice The Content of this Site is provided for informational purposes only; it is not intended nor recommended as a substitute for professional medical advice. You should not use the Content of this Site for diagnosing a health or fitness problem or disease. Always seek...
July 1, 2026
Privacy Statement (AU)
Privacy Statement Additional Privacy Information This site and all of the contents therein are the exclusive property of PharmaJet, Inc. The purpose of this site is to provide information about PharmaJet, our mission, our products, and our future plans. We reserve the right to alter, change or delete any material from these pages at any...
June 28, 2026
Privacy Statement (ZA)
Privacy Statement Additional Privacy Information This site and all of the contents therein are the exclusive property of PharmaJet, Inc. The purpose of this site is to provide information about PharmaJet, our mission, our products, and our future plans. We reserve the right to alter, change or delete any material from these pages at any...
Privacy Statement (BR)
Privacy Statement Additional Privacy Information This site and all of the contents therein are the exclusive property of PharmaJet, Inc. The purpose of this site is to provide information about PharmaJet, our mission, our products, and our future plans. We reserve the right to alter, change or delete any material from these pages at any...
Privacy Statement (EU)
Privacy Statement Additional Privacy Information This site and all of the contents therein are the exclusive property of PharmaJet, Inc. The purpose of this site is to provide information about PharmaJet, our mission, our products, and our future plans. We reserve the right to alter, change or delete any material from these pages at any...
Privacy Statement (UK)
Privacy Statement Additional Privacy Information This site and all of the contents therein are the exclusive property of PharmaJet, Inc. The purpose of this site is to provide information about PharmaJet, our mission, our products, and our future plans. We reserve the right to alter, change or delete any material from these pages at any...
Privacy Statement (US)
Privacy Statement Additional Privacy Information This site and all of the contents therein are the exclusive property of PharmaJet, Inc. The purpose of this site is to provide information about PharmaJet, our mission, our products, and our future plans. We reserve the right to alter, change or delete any material from these pages at any...
Privacy Statement (CA)
Privacy Statement Additional Privacy Information This site and all of the contents therein are the exclusive property of PharmaJet, Inc. The purpose of this site is to provide information about PharmaJet, our mission, our products, and our future plans. We reserve the right to alter, change or delete any material from these pages at any...
Cookie Policy (BR)
Cookie Policy (BR)
Cookie Policy (EU)
Cookie Policy (EU)
Cookie Policy (UK)
Cookie Policy (UK)
Opt-out preferences
Opt Out Preferences
Cookie Policy (CA)
Cookie Policy (CA)
Cookie Policy (AU)
Cookie Policy (AU)
Cookie Policy (ZA)
Cookie Policy (ZA)
A Narrative Review and Perspective on Implementation Research on Intradermal Delivery Methods for Fractionated-Dose Inactivated Poliomyelitis Vaccine
Recent trends in intradermal (ID) vaccination, as seen in the Global Polio Eradication Initiative and in the 2022 monkeypox (mpox) pandemic, are a reminder that vaccine administration to the dermis is a valuable alternative to the traditional routes of parenteral delivery.
May 13, 2026
Published Review Highlights Advantages of Needle-free Intradermal Delivery Over Traditional Needle and Syringe
GOLDEN, Colo. — May 19, 2026 — A growing emphasis on dose-sparing strategies and equitable vaccine access has renewed global interest in ID vaccine delivery. A recent, peer-reviewed publication in Qeios¹ evaluated the evidence on implementation of novel technologies for ID delivery of fractional-dose inactivated polio vaccine (fIPV).
May 8, 2026
PharmaJet® Tropis® Needle-free Injection System Selected to Deliver 1.4 Million Polio Vaccine Doses in Nigeria
GOLDEN, Colo. — May 7, 2026 — PharmaJet, a global leader in needle-free injection technology, today announced that its WHO-prequalified Tropis ID Needle-free Injection System will be used to deliver approximately 1.4 million doses of fractional inactivated polio vaccine (fIPV) during upcoming polio immunization campaigns in Nigeria. PharmaJet is partnering with the African Field Epidemiology Network (AFENET), to deploy Tropis for fIPV delivery to children under 5 years of age in Sokoto, a state in northwestern Nigeria.
May 5, 2026
Brazilian Tuberculosis Research Network to Evaluate PharmaJet® Needle-free Tropis® ID Injection Device as Delivery System for Tuberculin Skin Test
GOLDEN, Colo. — March 24, 2026 — PharmaJet®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner, Brazilian Tuberculosis Research Network (REDE-TB), plans to initiate a clinical study to evaluate the accuracy, workflow efficiency, safety, and acceptability of the tuberculin skin test (TST) using PharmaJet’s Tropis® ID Needle-free Injection System, compared to TST administered by needle.
Tags: Tropis, Tuberculosis
March 20, 2026
Protecting children without fear: A new way to vaccinate against polio in Afghanistan
On a cloudy early morning in Afghanistan’s Laghman province, Dr Arsala set out for Alingar—a rugged, mountain-wrapped district he had visited many times before. After 12 years as a Provincial Polio Officer, he knew the rhythm of polio campaigns: the early starts, the long drives, the predictable challenges. But this time felt unusually different. This time, he carries a new tool being introduced for the first time in Afghanistan’s polio programme.
January 20, 2026
Page 1 of 13